AR077396A2 - EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS - Google Patents

EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS

Info

Publication number
AR077396A2
AR077396A2 ARP100102440A ARP100102440A AR077396A2 AR 077396 A2 AR077396 A2 AR 077396A2 AR P100102440 A ARP100102440 A AR P100102440A AR P100102440 A ARP100102440 A AR P100102440A AR 077396 A2 AR077396 A2 AR 077396A2
Authority
AR
Argentina
Prior art keywords
hpv45
protein
produce
vph45
leaves
Prior art date
Application number
ARP100102440A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR077396A2 publication Critical patent/AR077396A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan moléculas sintéticas de ADN que codifican la proteína L1 del VPH45. De manera específica, la presente proporciona polinucleotidos que codifican la proteína L1 del VPH45, en la que dichos polinucleotidos se han optimizado para los codones para un nivel elevado de expresion en una célula de levadura. Las moléculas sintéticas se pueden usar para producir partículas pseudovíricas (VLP) del VPH45, y para producir vacunas y composiciones farmacéuticas que comprenden las VLP del VPH45. Las vacunas de la presente solicitud proporcionan una inmunoprofilaxis eficaz frente a la infeccion por el virus del papiloma mediante anticuerpos neutralizantes e inmunidad celular. Vector y célula huésped que comprenden las moléculas de ADN. Procedimiento para producir las VLP.
ARP100102440A 2003-09-29 2010-07-07 EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS AR077396A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50681203P 2003-09-29 2003-09-29

Publications (1)

Publication Number Publication Date
AR077396A2 true AR077396A2 (es) 2011-08-24

Family

ID=34421558

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP040103420A AR045804A1 (es) 2003-09-29 2004-09-22 Expresion optimizada de l1 del vph45 en levaduras
ARP100102440A AR077396A2 (es) 2003-09-29 2010-07-07 EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP040103420A AR045804A1 (es) 2003-09-29 2004-09-22 Expresion optimizada de l1 del vph45 en levaduras

Country Status (33)

Country Link
US (2) US7250170B2 (es)
EP (1) EP1673106B1 (es)
JP (4) JP5451960B2 (es)
KR (1) KR101165278B1 (es)
CN (1) CN1859923B (es)
AR (2) AR045804A1 (es)
AT (1) ATE435029T1 (es)
AU (1) AU2004277934B2 (es)
BE (1) BE2015C072I2 (es)
BR (1) BRPI0414845B8 (es)
CA (1) CA2539168C (es)
CY (2) CY1110525T1 (es)
DE (1) DE602004021828D1 (es)
DK (1) DK1673106T3 (es)
ES (1) ES2327530T3 (es)
FR (1) FR15C0083I2 (es)
HU (1) HUS1500063I1 (es)
IL (1) IL174458A (es)
IS (1) IS2694B (es)
LT (2) LTPA2015049I1 (es)
LU (1) LU92902I2 (es)
MX (1) MXPA06003457A (es)
MY (1) MY140664A (es)
NL (1) NL300776I2 (es)
NO (3) NO339932B1 (es)
NZ (1) NZ545834A (es)
PL (1) PL1673106T3 (es)
PT (1) PT1673106E (es)
RU (1) RU2360001C2 (es)
SI (1) SI1673106T1 (es)
TW (1) TWI350853B (es)
WO (1) WO2005032586A1 (es)
ZA (1) ZA200601961B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
TWI349036B (en) * 2004-03-24 2011-09-21 Merck Sharp & Dohme Optimized expression of hpv 52 l1 in yeast
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
CA2604909A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
EA013326B1 (ru) * 2005-04-26 2010-04-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
EP2059262B1 (en) * 2006-08-28 2013-08-21 Sungkyunkwan University Foundation for Corporate Collaboration A dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein
US7709010B2 (en) * 2007-03-09 2010-05-04 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
EP2223933B1 (en) * 2007-11-23 2016-01-27 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein l1 of human papilloma viruses
WO2010147268A1 (ko) 2009-06-19 2010-12-23 아이진 주식회사 자궁경부암 백신
WO2011149897A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
CN103717741B (zh) * 2011-06-15 2016-04-13 中央大学校产学协力团 用于提高人乳头瘤病毒l1蛋白产量的方法
JP6050811B2 (ja) 2011-06-24 2016-12-21 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アルミニウムアジュバントを含むｈｐｖワクチン製剤およびその産生方法
CN103215302B (zh) * 2012-01-21 2019-01-15 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN108624614A (zh) * 2012-03-28 2018-10-09 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN104120089B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN104120088B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN110295190A (zh) * 2013-05-17 2019-10-01 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv45 l1蛋白的方法
CN112280792B (zh) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 人乳头瘤病毒基因，及载体，菌株，表达方法
US9782470B2 (en) 2013-10-16 2017-10-10 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
EP3191505A2 (en) * 2014-09-11 2017-07-19 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
CN106282278B (zh) * 2015-06-29 2021-06-08 广东东阳光药业有限公司 一种人乳头瘤病毒l1蛋白的发酵方法
CN106701798B (zh) * 2015-08-12 2021-09-17 北京康乐卫士生物技术股份有限公司 45型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750050B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒45亚型蛋白表达
US11638754B2 (en) 2020-02-14 2023-05-02 Merck Sharp & Dohme Llc HPV vaccine
CN112680462B (zh) * 2020-12-29 2022-02-22 上海博唯生物科技有限公司 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
WO2023014853A1 (en) 2021-08-06 2023-02-09 Merck Sharp & Dohme Llc Hpv vaccine
JP2024532127A (ja) 2021-08-19 2024-09-05 メルク・シャープ・アンド・ドーム・エルエルシー 熱安定性脂質ナノ粒子およびその使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1152935A (zh) * 1994-05-16 1997-06-25 麦克公司 乳头状瘤病毒疫苗
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
IL131131A0 (en) 1997-02-07 2001-01-28 Merck & Co Inc Synthetic hiv gag genes
WO1998054339A1 (en) * 1997-05-27 1998-12-03 Hanil Synthetic Fiber Co., Ltd. PROCESS FOR PREPARING RECOMBINANT PROTEINS USING HIGHLY EFFICIENT EXPRESSION VECTOR FROM $i(SACCHAROMYCES CEREVISIAE)
WO1999002694A1 (en) 1997-07-09 1999-01-21 The University Of Queensland Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
WO2000009157A1 (en) * 1998-08-14 2000-02-24 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
EP1140974B1 (en) * 1998-12-23 2005-03-02 Merck & Co., Inc. Neutralizing assay using human papillomavirus virus-like particles
JP4799789B2 (ja) * 1999-08-25 2011-10-26 メルク・シャープ・エンド・ドーム・コーポレイション ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
BR0112637A (pt) 2000-07-21 2003-06-10 Glaxo Group Ltd Sequências do vìrus do papiloma códon-otimizadas
US20040063188A1 (en) * 2002-02-14 2004-04-01 Novavax, Inc. Kit for treating gastrointestinal tract
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
AU2004224335B2 (en) 2003-03-24 2010-01-28 Merck Sharp & Dohme Llc Optimized expression of HPV 31 L1 in yeast

Also Published As

Publication number Publication date
MXPA06003457A (es) 2006-06-05
NL300776I1 (es) 2015-12-29
FR15C0083I1 (fr) 2016-08-01
ZA200601961B (en) 2007-05-30
IL174458A (en) 2014-06-30
JP2011152137A (ja) 2011-08-11
TW200521233A (en) 2005-07-01
IS8362A (is) 2006-03-20
JP2016136947A (ja) 2016-08-04
ATE435029T1 (de) 2009-07-15
MY140664A (en) 2010-01-15
KR20070029628A (ko) 2007-03-14
TWI350853B (en) 2011-10-21
NO20061876L (no) 2006-04-28
BE2015C072I2 (es) 2023-12-14
AU2004277934A1 (en) 2005-04-14
LU92902I2 (fr) 2016-03-08
RU2006114701A (ru) 2007-11-10
CY2015050I2 (el) 2016-06-22
PT1673106E (pt) 2009-09-22
FR15C0083I2 (fr) 2016-11-25
HUS1500063I1 (hu) 2016-02-29
US7250170B2 (en) 2007-07-31
CN1859923B (zh) 2012-09-05
PL1673106T3 (pl) 2009-12-31
US20080138361A1 (en) 2008-06-12
NO2017012I1 (no) 2017-04-05
DK1673106T3 (da) 2009-11-09
CY2015050I1 (el) 2016-06-22
JP2007507207A (ja) 2007-03-29
WO2005032586A1 (en) 2005-04-14
RU2360001C2 (ru) 2009-06-27
LTPA2015049I1 (lt) 2016-01-11
US7482015B2 (en) 2009-01-27
EP1673106B1 (en) 2009-07-01
CA2539168C (en) 2011-05-31
KR101165278B1 (ko) 2012-07-23
JP5451960B2 (ja) 2014-03-26
US20060240040A1 (en) 2006-10-26
IS2694B (is) 2010-11-15
CY1110525T1 (el) 2015-04-29
SI1673106T1 (sl) 2009-12-31
IL174458A0 (en) 2006-08-01
ES2327530T3 (es) 2009-10-30
CN1859923A (zh) 2006-11-08
BRPI0414845B8 (pt) 2021-06-15
EP1673106A1 (en) 2006-06-28
NZ545834A (en) 2009-02-28
NO339932B1 (no) 2017-02-20
CA2539168A1 (en) 2005-04-14
BRPI0414845A (pt) 2006-11-21
DE602004021828D1 (de) 2009-08-13
LTC1673106I2 (lt) 2017-05-10
NO2022051I1 (no) 2022-11-30
AR045804A1 (es) 2005-11-16
AU2004277934B2 (en) 2009-09-17
NL300776I2 (es) 2015-12-29
BRPI0414845B1 (pt) 2020-10-13
JP2014221052A (ja) 2014-11-27

Similar Documents

Publication Publication Date Title
AR077396A2 (es) EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS
AR046835A1 (es) Expresion optimizada de l1 de hpv58 en levadura
ECSP056032A (es) Expresión optimizada de hpv 31 l1 en levadura
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
TR201908199T4 (tr) HPV'ye karşı aşılar.
PE20201264A1 (es) Variantes de capsides de virus adenoasociados y metodos de uso de estas
MY148656A (en) Optimized expression of hpv 52 l1 in yeast.
SG165378A1 (en) Functional influenza virus-like particles (vlps)
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
WO2008034388A8 (fr) Particules virales de protéines de la capside provenant du papillomavirus humain de type 16/58/18/6/11 et leur procédé de préparation et leurs utilisations
AR039005A1 (es) Antigenos virales
AR108781A1 (es) Aumento de la inmunogenicidad del péptido l2 de virus de papiloma humano (hpv)
EA201170965A1 (ru) Усовершенствованные вакцины вируса человеческой папилломы и способы их использования
DE602005019238D1 (de) Oteinen
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.
AR051923A1 (es) Secuencias de acidos nucleicos que codifican proteinas capaces de asociarse en particulas tipo virus
EA201170264A1 (ru) Вакцина против hpv
PE20230349A1 (es) Vacunas para la papilomatosis respiratoria recurrente y metodos para usar estas
MY162658A (en) Genes encoding major capsid protein l1 of human papilloma virus and use of the same
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
AR045815A1 (es) Composiciones farmaceuticas que contienen antigenos del virus de papiloma humano
TW200607858A (en) Optimized expression of HPV 31 L1 in yeast
TH82139B (th) การแสดงออกที่ถูกทำให้เหมาะสมของ hpv 45l1 ในยีสต์

Legal Events

Date Code Title Description
FC Refusal